These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 29770133)

  • 61. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone.
    Devine SM; Brown RA; Mathews V; Trinkaus K; Khoury H; Adkins D; Vij R; Sempek D; Graubert T; Tomasson M; Goodnough LT; DiPersio JF
    Bone Marrow Transplant; 2005 Sep; 36(6):531-8. PubMed ID: 16025152
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
    Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E
    Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The impact of donor characteristics on the invariant natural killer T cells of granulocyte-colony-stimulating factor-mobilized marrow grafts and peripheral blood grafts.
    Hong Y; Zhao XY; Yu XX; Bian ZL; Chang YJ; Wang Y; Zhang XH; Xu LP; Huang XJ; Zhao XS
    Transpl Immunol; 2018 Jun; 48():55-59. PubMed ID: 29475092
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants.
    Volpi I; Perruccio K; Tosti A; Capanni M; Ruggeri L; Posati S; Aversa F; Tabilio A; Romani L; Martelli MF; Velardi A
    Blood; 2001 Apr; 97(8):2514-21. PubMed ID: 11290617
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Effect of rhG-CSF Mobilization on S1P5 Expression in T Lymphocyte Subsets of Allo-HSCT Donors].
    Li M; Guan LX; Gu ZY; Zhao SS; Wang FY; Wei HP; Wang L; Li HH; Bo J; Gao CJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1132-6. PubMed ID: 27531788
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
    Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
    Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors.
    Suzuya H; Watanabe T; Nakagawa R; Watanabe H; Okamoto Y; Onishi T; Abe T; Kawano Y; Kagami S; Takaue Y
    Vox Sang; 2005 Nov; 89(4):229-35. PubMed ID: 16262756
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Acute lung Injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone.
    Arimura K; Inoue H; Kukita T; Matsushita K; Akimot M; Kawamata N; Yamaguchi A; Kawada H; Ozak A; Arima N; Te C
    Haematologica; 2005 Mar; 90(3):ECR10. PubMed ID: 15753051
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
    Sosman JA; Stiff P; Moss SM; Sorokin P; Martone B; Bayer R; van Besien K; Devine S; Stock W; Peace D; Chen Y; Long C; Gustin D; Viana M; Hoffman R
    J Clin Oncol; 2001 Feb; 19(3):634-44. PubMed ID: 11157013
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®).
    Antelo ML; Zabalza A; Sánchez Antón MP; Zalba S; Aznar M; Mansilla C; Ramírez N; Olavarría E
    J Clin Apher; 2016 Feb; 31(1):48-52. PubMed ID: 26011178
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical outcomes and graft characteristics in pediatric hematopoietic stem cell transplantation: Effect of granulocyte-colony stimulating factor priming.
    Fettah A; Özbek N; Azık F; Tavil B; Özgüner M; Avcı Z; Işık P; Yaralı N; Uçkan D; Tunç B
    Transfus Apher Sci; 2015 Jun; 52(3):332-8. PubMed ID: 25779226
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation.
    Lv M; Zhao XS; Hu Y; Chang YJ; Zhao XY; Kong Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Am J Hematol; 2015 Jan; 90(1):E9-E16. PubMed ID: 25303038
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Regulatory CD4+CD25hi T cells conserve their function and phenotype after granulocyte colony-stimulating factor treatment in human hematopoietic stem cell transplantation.
    Noël G; Bruniquel D; DeGuibert S; Birebent B; Grosset JM; Bernard M; Dauriac C; Lamy-de-la-Chapelle T; Semana G; Brinster C
    Hum Immunol; 2008 Jun; 69(6):329-37. PubMed ID: 18571003
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
    Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Allogeneic hematopoietic stem cell transplantations].
    Michallet M
    Transfus Clin Biol; 2011 Apr; 18(2):235-45. PubMed ID: 21466967
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyte-colony-stimulating factor-mobilized marrow harvests and peripheral blood harvests.
    Wang YT; Zhao XY; Zhao XS; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Huang XJ
    Transfusion; 2015 Dec; 55(12):2874-81. PubMed ID: 26261077
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation.
    Minculescu L; Fischer-Nielsen A; Haastrup E; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Sengelov H; Marquart HV
    Front Immunol; 2020; 11():1068. PubMed ID: 32547559
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
    Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
    Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor.
    Gyger M; Stuart RK; Perreault C
    Bone Marrow Transplant; 2000 Jul; 26(1):1-16. PubMed ID: 10918400
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Administration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation.
    Sautois B; Baudoux E; Salmon JP; Michaux S; Schaaf-Lafontaine N; Pereira M; Paulus JM; Fillet G; Beguin Y
    Haematologica; 2001 Nov; 86(11):1209-18. PubMed ID: 11694408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.